摘要
目的探讨利拉鲁肽联合甘精胰岛素治疗新诊断2型糖尿病的疗效。方法将80例新诊断2型糖尿病患者随机分为2组。对照组患者给予预混胰岛素治疗,联合组患者则采用利拉鲁肽联合甘精胰岛素治疗。比较2组患者治疗前后血糖、血脂、一般资料与不良反应。结果联合组患者治疗后4、12周空腹血糖(FPG)、餐后2 h血糖(2 hPG)与糖化血红蛋白(Hb A1c)水平均显著低于对照组(P <0. 05),总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均显著低于对照组(P <0. 05),高密度脂蛋白胆固醇(HDL-C)水平显著高于对照组(P <0. 05)。联合组治疗后4、12周体质量、腰围与体质量指数均显著低于对照组(P <0. 05)。2组患者药物不良反应发生率差异无统计学意义(P> 0. 05)。结论利拉鲁肽联合甘精胰岛素治疗新诊断2型糖尿病的疗效显著。
Objective To investigate the efficiency of liraglutide combined with insulin glargine in treating patients with newly diagnosed type2diabetes.Methods Totally80patients with newly diagnosed type2diabetes were randomly divided into two groups.Patients in the control group were given premixed insulin treatment,while patients in the combined group were treated with liraglutide and insulin glargine.Blood glucose,blood lipids,general materials and adverse reactions before and after treatment were compared between the two groups.Results The levels of fasting blood glucose(FPG),2hour postprandial blood glucose(2hPG)and glycosylated hemoglobin(HbA1c)in the combined group were significantly lower than those in the control group(P<0.05),the levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)were significantly lower than those in the control group(P<0.05),and the level of high density lipoprotein cholesterol(HDL-C)was significantly lower than that in the control group(P<0.05).The body mass,waist circumference and body mass index of the combined group were significantly lower than those of the control group at4and12weeks after treatment(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Liraglutide combined with insulin glargine is effective in treating patients with newly diagnosed type2diabetes.
作者
郭晓静
冯晓荣
苏佩合
GUO Xiaojing;FENG Xiaorong;SU Peihe(General Hospital of Xi′an Aerospace, Xi′an, Shaanxi, 710100)
出处
《实用临床医药杂志》
CAS
2018年第23期43-46,共4页
Journal of Clinical Medicine in Practice
基金
陕西省卫生厅科研基金项目(2016D03701)
